Contact us

Investing in the bright future of advanced therapies

We are supported by top-tier healthcare and technology investors who share our vision of becoming a global leader in advanced therapies.

Spain as the European leader in cell therapy

Idea Therapeutics is part of the Spanish biotechnology ecosystem, which is becoming a Europen leader. The Spanish Agency for Medicines and Medical Devices (AEMPS) has authorized 930 studies in 2024, becoming the most European regulatory agency with most clinical trials approved. Regarding advanced therapy medicines, Spain is also a leader in Europe with a total of 52 trials authorized in 2024, with a promising future ahead. (Source: ASEBIO)

European regulatory agency in clinical trial approvals
Nº 0
Studies approved by AEMPS in 2024
0
ATMP trials approved in 2024
0

Discover relevant data about our key markets below

The androgenetic alopecia market

Prevalence Men [1-4]

by age 30
< 0 %
by age 50
< 0 %

Prevalence Women [4-8]

by age 50
0 %
by age 70
< 0 %

Market value data [9,10]

Market value alopecia 2023
$ 0 M
CAGR alopecia market 2024-2030
0 %
MarketValue for stem cell therapies 2024
$ 0 M
CAGR stem cell therapy market 2025-2030
0 %

Institutions

External advisors

CDMO

Bibliography

  1. Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. Mar 1951;53(3):708-28. doi:10.1111/j.1749-6632.1951.tb31971.x
  2. Yip L, Zaloumis S, Irwin D, Severi G, Hopper J, Giles G, Harrap S, Sinclair R, Ellis J. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol. Aug 2009;161(2):289-94. doi:10.1111/j.1365-2133.2009.09186.x
  3. Severi G, Sinclair R, Hopper JL, English DR, McCredie MR, Boyle P, Giles GG. Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors. Br J Dermatol. Dec 2003;149(6):1207-13. doi:10.1111/j.1365-2133.2003.05565.x
  4. Norwood OT. Male pattern baldness: classification and incidence. South Med J. Nov 1975;68(11):1359-65. doi:10.1097/00007611-197511000-00009
  5. Salman KE, Altunay IK, Kucukunal NA, Cerman AA. Frequency, severity and related factors of androgenetic alopecia in dermatology outpatient clinic: hospital-based cross-sectional study in Turkey. An Bras Dermatol. Jan-Feb 2017;92(1):35-40. doi:10.1590/abd1806-4841.20175241
  6. Wang TL, Zhou C, Shen YW, Wang XY, Ding XL, Tian S, Liu Y, Peng GH, Xue SQ, Zhou JE, Wang RL, Meng XM, Pei GD, Bai YH, Liu Q, Li H, Zhang JZ. Prevalence of androgenetic alopecia in China: a community-based study in six cities. Br J Dermatol. Apr 2010;162(4):843-7. doi:10.1111/j.1365-2133.2010.09640.x
  7. He F, Shen M, Zhao Z, Liu Y, Zhang S, Tang Y, Xie H, Chen X, Li J. Epidemiology and disease burden of androgenetic alopecia in college freshmen in China: A population-based study. PLoS One. 2022;17(2):e0263912. doi:10.1371/journal.pone.0263912
  8. Bas Y, Seckin HY, Kalkan G, Takci Z, Citil R, Önder Y, Sahin S, Demir AK. Prevalence and types of androgenetic alopecia in north Anatolian population: A community-based study. J Pak Med Assoc. Aug 2015;65(8):806-9.
  9. Grand View Research. Alopecia Market Analysis. [Accessed February 10, 2025]. Available from: https://www.grandviewresearch.com/industry-analysis/alopecia-market
  10. Grand View Research. Stem Cell Therapy Market Analysis. [Accessed February 10, 2025]. Available from: https://www.grandviewresearch.com/industry-analysis/stem-cell-therapy-market-report